Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can exercise tests uncover hidden heart strain in myeloma patients?

NCT ID NCT07851493

Knowledge-focused Sponsor: Technical University of Munich Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 01, 2026 · Last updated Oct 06, 2026 · Updated 3 times

Summary

Researchers at the Technical University of Munich are studying 80 people newly diagnosed with multiple myeloma who have not started chemotherapy and whose resting heart scans look normal or nearly normal. The study tests whether exercise testing can reveal a hidden heart limitation that resting scans miss. Participants complete one detailed heart and fitness assessment before chemotherapy, then return for check-ups at 3 and 12 months. The goal is to see if exercise-based heart markers relate to subtle heart tissue changes and to heart-related hospital stays or death.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If exercise testing reveals hidden heart limits, doctors could identify myeloma patients who need closer heart monitoring or gentler chemotherapy. This could help prevent heart complications during cancer treatment.
What could go wrong
This is a small observational study of 80 people at one center, so its findings may not apply to everyone with myeloma. Exercise testing and heart scans carry small risks, and the study cannot prove that early detection changes outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with newly diagnosed multiple myeloma who have not yet initiated chemotherapy, recruited via the haemato-oncology outpatient clinics.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically or cytologically confirmed newly diagnosed multiple myeloma and chemotherapy not yet initiated * Resting echocardiogram with preserved left ventricular ejection fraction (≥50%) and at most mild (grade I) diastolic dysfunction with no echocardiographic signs of clinically manifest cardiac involvement * Age 18-99 years * Written informed consent * Sufficient German or English language skills Exclusion Criteria: * New York Heart Failure Association Class IV heart failure, or recent decompensated heart failure requiring inpatient recompensation * Suspected new or progressive coronary artery disease * Estimated glomerular filtration rate \<30 mL/min/1.73m², or contraindication to gadolinium-based contrast agents * Severe anaemia, defined as haemoglobin \<8 g/dL at baseline * Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Exercise behavior are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Exercise behavior Multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Preventive Sports Medicine and Sports Cardiology, TUM School of Medicine and Health, Klinikum rechts der Isar

    RECRUITING

    Munich, Bavaria, 81675, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.